Literature DB >> 12720474

Toward an understanding of bipolar disorder and its origin.

A John Rush1.   

Abstract

Bipolar disorder, a disease with significant morbidity and mortality, continues to present diagnostic and clinical challenges. Lifetime prevalence of bipolar I disorder has been estimated at 1.3%, with an equal distribution between males and females. Recognition of the illness may take years, but most patients are diagnosed before the age of 30. The role of genetic influences in bipolar disease is supported by family studies and high concordance rates among monozygotic twins. Current speculation proposes a likely interaction between genetic predisposition and environmental influences, including stressful life events. Diagnostic work-up should exclude mania secondary to drug use or general medical causes, particularly in patients whose symptoms begin after age 30 and in those with no family history of bipolar or unipolar disease. Patients with cyclothymia or thyroid dysfunction or postpartum women are at particular risk for bipolar disease. Substance abuse, which is extremely common among patients with bipolar disorder, interferes with diagnosis and can worsen the course of the disease. Alcohol dependence has been reported in approximately one third of those with bipolar I and one fifth of those with bipolar II disorder. To facilitate early diagnosis and effective management, clinicians should be aware of the risk factors, possible causes, and comorbidities of bipolar disease.

Entities:  

Mesh:

Year:  2003        PMID: 12720474

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

1.  Incurring greater health care costs: risk stratification of employees with bipolar disorder.

Authors:  Richard A Brook; Krithika Rajagopalan; Nathan L Kleinman; James E Smeeding; Truman J Brizee; Harold H Gardner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  Maternal serum cytokine levels and risk of bipolar disorder.

Authors:  Keely Cheslack-Postava; Serge Cremers; Yuanyuan Bao; Ling Shen; Catherine A Schaefer; Alan S Brown
Journal:  Brain Behav Immun       Date:  2016-07-29       Impact factor: 7.217

3.  The noradrenaline metabolite MHPG is a candidate biomarker between the depressive, remission, and manic states in bipolar disorder I: two long-term naturalistic case reports.

Authors:  Masatake Kurita; Satoshi Nishino; Yukio Numata; Yoshiro Okubo; Tadahiro Sato
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-11       Impact factor: 2.570

Review 4.  Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode.

Authors:  Masatake Kurita
Journal:  Neuropsychiatr Dis Treat       Date:  2016-09-20       Impact factor: 2.570

5.  Improving early recognition and intervention in people at increased risk for the development of bipolar disorder: study protocol of a prospective-longitudinal, naturalistic cohort study (Early-BipoLife).

Authors:  Andrea Pfennig; Karolina Leopold; Julia Martini; Anne Boehme; Martin Lambert; Thomas Stamm; Felix Bermpohl; Andreas Reif; Sarah Kittel-Schneider; Georg Juckel; Andreas J Fallgatter; Tilo Kircher; Andreas Jansen; Steffi Pfeiffer; Christina Berndt; Maren Rottmann-Wolf; Cathrin Sauer; Philipp Ritter; Christoph U Correll; Andreas Bechdolf; Irina Falkenberg; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2020-07-01

6.  The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study.

Authors:  Masatake Kurita; Satoshi Nishino; Yukio Numata; Yoshiro Okubo; Tadahiro Sato
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.